Michael Ehlers (Replicate)
With a fresh $75M, Michael Ehlers' latest take on non-viral gene therapy is ready for takeoff
When Michael Ehlers hit the exit at Biogen a few years ago to become a venture partner at ATP, he also took the lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
